Researchers from Boston College, Boston University, and Giner Labs have designed a small graphene-based multiplexed bio-sensor that detects opioid byproducts in wastewater.
The novel device uses graphene-based field effect transistors to detect four different synthetic and natural opioids at once, while shielding them from wastewater’s harsh elements. When a specific opioid metabolite attaches to a molecular probe on the graphene, it changes the electrical charge on the graphene. These signals are easily read electronically for each probe attached to the device.
The device responds to a primary challenge of the opioid epidemic: determining the amount and kind of drugs being used in a community. Privacy concerns and limited resources are barriers to testing large populations. An alternative approach is wastewater-based epidemiology, similar to testing wastewater to measure community levels of coronavirus infection during the pandemic.
Wastewater testing is an emerging strategy that can defeat limitations and stigma associated with individual drug testing, and it provides a more objective measure of drug use at neighborhood level, said Giner Labs Vice President for Advanced Materials Avni Argun, a co-leader of the project. While wastewater testing has been widely conducted in Europe, only a few studies exist in the US. Rapid and portable nature of the team’s device would allow wide scale population testing at low cost and high geographical resolution.
The team’s prototype could provide a cheaper and faster tool for use by public health officials trying to determine the level of opioid usage and the impact of community-wide treatment interventions.
While graphene has been used before for sensing biological samples, the team’s work is the first demonstration that the material could be used with wastewater, Burch said.
In addition, it is the first demonstration of using graphene-based field effect transistors, an electronic device to read the amount of charge, to detect multiple targets at the same time, according to the report.
The breakthrough was enabled by the design and implementation of the graphene electronic multiplexed sensor (GEMS) platform, Burch said. The platform enables the sensing of four different target molecules at once, while shielding them from harsh elements in waste water, samples of which were provided by the Mass. Alternative Septic System Test Center (MASSTC) on Cape Cod.
The team fitted the graphene probes with aptamers, strands of DNA designed to only attach to a specific molecule in this case, metabolites of various opioids in waste water. When the aptamer attaches to the drug it folds, bringing more charge to graphene. The amount of charge on the graphene is monitored to detect the presence of a specific opioid metabolite, Burch said.
These aptamers were attached to our graphene devices and when trapping the drug the induced charge on the graphene was read electronically, Burch said. Our fabrication process and design resulted in a lower limit of detection an order of magnitude better than previous reports by other methods.
Prior sampling tools faced the limitations because they required the shipping of samples and testing in a laboratory setting. Those requirements impose costs that limit wide adoption and use in communities without sufficient resources. By overcoming those limits, the graphene device can provide nearly real-time monitoring in multiple locations, which could also help distribute resources such as first responders or specific intervention strategies, Burch said.
This is the first such sensor that can achieve it with such a simple and easy-to-use setup a single GEMS platform is the size of a penny, Burch added.
The success of GEMS resulted from a long-term collaboration led by Burch, bringing together the DNA expertise of Boston College Associate Professor of Biology Tim van Opijnen, graphene cultivation by Boston University chemist Xi Ling, and biosensor assay development expertise of Argun and scientists from Giner Labs.
Burch said the team was surprised at how well the device withstood the harsh wastewater environment. He said his lab is working with Giner Labs under NIDA small business innovation research (SBIR) funding to develop the devices for eventual commercial use.
We are also working to see what else the platform can be used for, such as rapid at-home testing of viral infections and/or the presence of pathogens in wastewater, Burch said.
The work of Argun’s team at Giner Labs is funded by the NIH’s National Institute on Drug Abuse, which is working with researchers to develop smart city tools that would assist public health surveillance programs addressing drug use and abuse. Additional funding for the project came from the National Science Foundation, National Institutes of Health, and the Office of Naval Research.